An open-label extension study to study 100185, to evaluate long-term safety, efficacy and optimal dosing frequency of 750mg intravenous mepolizumab in subjects with hypereosinophilic syndrome.
- Registry ID
- EUCTR2004-000930-35
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- GLAXO SMITHKLINE
- Start date
- 2005-05-26
- Last update
- 2026-08-16
Conditions
- Hypereosinophilic syndrome (HES)
- HES
Summary
Valutare la sicurezza a lungotermine di 750 mg di mepolizumab somministrato per via endovenosa, in soggetti con HES con una frequenza massima di dosaggio di una volta al mese.
Locations
View on source registry